Effects of tacrine and bis(7)-tacrine (0.25-20 lmol ⁄ kg, s.c.) on cognitive behaviour in cycloheximide (CYH)-treated mice were investigated. Cognitive behaviour was assessed by open-field test and step-through task with a 24-hr retention interval. Drugs or vehicle was given 30 min. prior to the first session. Although CYH treatment (110 mg ⁄ kg, i.p.) alone did not affect the locomotor activity of mice, CYH treatment in combination with tacrine (20 lmol ⁄ kg) decreased the locomotor activity by 37% in the acquisition session, when compared with mice treated with CYH alone. Bis-(7) tacrine cotreatment did not produce any detectable effect on locomotor activity. During the retention trial, tacrine (5 lmol ⁄ kg) or bis(7)-tacrine (1 lmol ⁄ kg) enhanced the retention latency (by 3.8-or 1.4-fold, respectively) in CYH-treated mice. In both training and retention trials, CYH treatment increased the number of footshocks (by 50% and 11.3-fold, respectively). However, during the retention (but not training) trial, tacrine (5 lmol ⁄ kg) or bis(7)-tacrine (1 lmol ⁄ kg) decreased the footshocks (by 8.6-fold or 39%, respectively) in CYH-treated mice. Combined treatment with CYH and bis(7)-tacrine (but not tacrine) resulted in an increased mortality rate in mice. The results indicated that tacrine and bis (7)-tacrine improved the amnesia caused by CYH treatment. However, the combined treatment with bis(7)-tacrine and CYH administration caused acute toxicity.Acetylcholine (ACh) is widely distributed in the central and peripheral nervous system. ACh released from cholinergic nerve terminals activates receptors at both pre-synaptic and post-synaptic sites. It is then hydrolysed by acetylcholinesterase (AChE) into choline and acetyl coenzyme A. Cholinergic nerve in the brain may play an important role in many cognitive functions, such as cortical modulation of sensory information processing, attention, memory and learning [1][2][3]. Therapeutic strategies adopting cholinergic precursor loading and AChE inhibitors, which can increase ACh concentration in vivo, were used for treating cognitive impairment occurring in Alzheimer's disease (AD) and geriatric memory dysfunction [4][5][6].The cognitive enhancement and AChE inhibition afforded by tacrine, a reversible AChE inhibitor, has been widely studied. The administration of tacrine is often accompanied by abnormal behaviour and a decline in physical strength in patients [7,8]. Bis(7)-tacrine is a novel anti-AD agent that can reversibly inhibit AChE 150-fold more potently than tacrine in rat brains [9,10]. The cognitive enhancement of bis(7)-tacrine was observed in rats treated with scopolamine, a muscarinic cholinergic receptor antagonist that causes memory loss, and AF64A, a cholinergic neuron-specific neurotoxin [11,12]. Our previous works have shown that both tacrine and bis(7)-tacrine inhibited the locomotor activity in normal mice and improved the impairment of open-field and passive avoidance response memory in mice treated with scopolamine [13][14][15]. Cycloheximi...